Gonzalo López

发表

Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design

Gregory P. Way, Jo Lynne Rokita, D. Haussler, 2019, Cell reports.

Genomic landscape of 261 childhood cancer patient-derived xenograft models

Gregory P. Way, Jo Lynne Rokita, D. Haussler, 2019, bioRxiv.

Identification of GPC2 as an Oncoprotein and Candidate Immunotherapeutic Target in High-Risk Neuroblastoma.

J. Khan, Jun S. Wei, M. Marra, 2017, Cancer cell.

Integrative genomics identifies lncRNA regulatory networks across 1,044 pediatric leukemias and extra-cranial solid tumors

S. Grant, D. Gerhard, J. Maris, 2020, bioRxiv.

Somatic structural variation targets neurodevelopmental genes and identifies SHANK2 as a tumor suppressor in neuroblastoma

D. Gerhard, J. Khan, Jun S. Wei, 2019, bioRxiv.

Pediatric high-grade glioma resources from the Children’s Brain Tumor Tissue Consortium

Allison P. Heath, Jena V. Lilly, Alex S. Felmeister, 2019, Neuro-oncology.

Pediatric High Grade Glioma Resources From the Children’s Brain Tumor Tissue Consortium (CBTTC) and Pediatric Brain Tumor Atlas (PBTA)

Allison P. Heath, Jena V. Lilly, Alex S. Felmeister, 2019, bioRxiv.

Somatic structural variation targets neurodevelopmental genes and identifies SHANK2 as a tumor suppressor in neuroblastoma.

D. Gerhard, J. Khan, Jun S. Wei, 2020, Genome research.

Telomere Maintenance Mechanisms Define Clinical Outcome in High-Risk Neuroblastoma

Jo Lynne Rokita, D. Wheeler, J. Maris, 2020, Cancer Research.

Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design

David Haussler, Jacob Pfeil, Olena Morozova Vaske, 2019, Cell reports.

ALT in Pediatric Brain Tumors Can Occur without ATRX Mutation and is Enriched in Patients with Pathogenic Germline MMR Variants

Marilyn M. Li, Rebecca S. Kaufman, Jo Lynne Rokita, 2022, bioRxiv.

Alternative lengthening of telomeres (ALT) in pediatric high-grade gliomas can occur without ATRX mutation and is enriched in patients with pathogenic germline mismatch repair (MMR) variants

Marilyn M. Li, Matthew R. Lueder, Rebecca S. Kaufman, 2022, bioRxiv.

11q deletion in neuroblastoma: a review of biological and clinical implications

J. Maris, F. Gumy-Pause, M. Ansari, 2017, Molecular Cancer.

Integrated Proteogenomic Characterization across Major Histological Types of Pediatric Brain Cancer

Guo Ci Teo, Allison P. Heath, Marilyn M. Li, 2020, Cell.

Pediatric high-grade glioma resources from the Children’s Brain Tumor Tissue Consortium

Allison P. Heath, Jena V. Lilly, Alex S. Felmeister, 2019, bioRxiv.

Germline pathogenic variants in 786 neuroblastoma patients

Trevor J Pugh, Rebecca S. Kaufman, H. Hakonarson, 2023, medRxiv.

Germline 16p11.2 Microdeletion Predisposes to Neuroblastoma.

H. Hakonarson, A. Olshan, S. Diskin, 2019, American journal of human genetics.

GAS7 Deficiency Promotes Metastasis in MYCN-Driven Neuroblastoma

Hu Li, A. Look, C. Ung, 2021, Cancer Research.

LMO1 Synergizes with MYCN to Promote Neuroblastoma Initiation and Metastasis.

Hu Li, D. Neuberg, A. Look, 2017, Cancer cell.

Svpluscnv: Analysis and Visualization of Complex Structural Variation Data

Adam A. Margolin, Federico M Giorgi, Adam A Margolin, 2020, Bioinform..

Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design

D. Haussler, D. Wheeler, P. Raman, 2019, Cell reports.

Identification of GPC2 as an Oncoprotein and Candidate Immunotherapeutic Target in High-Risk Neuroblastoma.

J. Khan, Jun S. Wei, M. Marra, 2017, Cancer cell.

LMO1 Synergizes with MYCN to Promote Neuroblastoma Initiation and Metastasis.

Hu Li, D. Neuberg, A. Look, 2017, Cancer cell.